Array BioPharma (NASDAQ:ARRY) was up more than 9% in pre-market trade after reporting positive study results for its asthma treatment. The company said, ARRY-502, an oral CRTh2 antagonist, was studied in a 184-patient placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma, a population representing more than 12 million patients in the U.S. ARRY-502 met the primary endpoint in the trial, … Continue reading Array Biopharma (NASDAQ:ARRY) Jumping Pre-Bell, SolarCity (NASDAQ:SCTY), Nu Skin Enterprises (NYSE:NUS) Slip